COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

Observational Registry of the Treatment of Glanzmann's Thrombasthenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01476423
Recruitment Status : Completed
First Posted : November 22, 2011
Last Update Posted : December 23, 2014
Information provided by (Responsible Party):
Novo Nordisk A/S

Brief Summary:

This observational registry is conducted in Europe, Asia, Africa and the United States of America (USA).

The purpose of the registry is to evaluate the efficacy and safety of activated recombinant human factor VII (rFVIIa) during bleeding episodes and for the prevention of bleeding during invasive procedures/surgery in patients with Glanzmann's thrombasthenia (GT) with past or present refractoriness to platelet transfusions. Attention will be directed towards complications related to thrombo-embolic events and concomitant medications especially antifibrinolytics.

Condition or disease Intervention/treatment
Congenital Bleeding Disorder Glanzmann's Disease Drug: activated recombinant human factor VII

Layout table for study information
Study Type : Observational
Actual Enrollment : 218 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Treatment of Glanzmann's Thrombasthenia: A Prospective Observational Registry
Study Start Date : January 2004
Actual Primary Completion Date : October 2011
Actual Study Completion Date : October 2011

Group/Cohort Intervention/treatment
A Drug: activated recombinant human factor VII
A prospective, observational multi-national registry collecting data and evaluating the efficacy and safety of rFVIIa in patients with GT with past or present refractoriness to platelet transfusions. The registry will also collect data from a broader range of GT patients treated with systemic haemostatic treatment (with or without antifibrinolytic drugs or other agents) used in the clinics. Data collection will continue for a maximum of six years. Baseline data as well as data obtained during either bleeding episodes or invasive procedures/surgeries will be recorded in the registry.

Primary Outcome Measures :
  1. For bleeding episodes: Overall efficacy evaluated by the caregiver/patient [ Time Frame: within 30 days of end of treatment ]
  2. For surgery including invasive and dental procedures: Haemoglobin level [ Time Frame: prior to surgery and 24 hours after surgery ]
  3. For surgery including invasive and dental procedures: Overall haemostatic evaluation by the surgeon [ Time Frame: 24 hours after surgery ]

Secondary Outcome Measures :
  1. Changes in laboratory parameters (prothrombin time, platelet count, fibrinogen), if available [ Time Frame: at the time of administration and two hours after the administration of rFVIIa ]
  2. Adverse Events (AEs) [ Time Frame: during treatment episodes ]
  3. Serious Adverse Events (SAEs) [ Time Frame: during treatment episodes ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with GT. There is no limit to the number of bleeding episodes or preventions of bleeding during invasive procedures/surgery that can be entered for each patient within the lifetime of the registry. Patients will receive standard care according to local practice, thus any systemic haemostatic treatment (with or without antifibrinolytic drugs or other agents) considered useful by the centres for treatment of GT, are included in the registry.

Inclusion Criteria:

  • Patients with congenital GT defined as patients with lifelong bleeding tendency characterised by impaired or absent platelet aggregation, impaired clot retraction and prolonged bleeding time or prolonged platelet function analyser closure time. The patient has normal platelet counts and platelet morphology. Optional diagnosis criteria are quantitative or qualitative evaluation of GP (Glycoprotein) IIb/IIIa receptor including flow cytometry and identification of gene defects
  • Signed informed consent by the patient or next of kin or legally acceptable representative to collect data on treatment of a given bleeding episode or surgical event as specified in the protocol. If informed consent is provided by the next of kin or legally acceptable representative, consent must also be obtained from the patient as soon as he/she is able to do so. Informed consent must be obtained before entry of data into the registry

Exclusion Criteria:

  • Patients with acquired thrombasthenic states caused by autoimmune disorders (acute or chronic) or drugs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01476423

Layout table for location information
United States, New Jersey
Novo Nordisk Clinical Trial Call Center
Princeton, New Jersey, United States, 08540
Algiers, Algeria, 16035
Vienna, Austria, A-1010
Brussels, Belgium, 1070
Sofia, Bulgaria, 1407
Paris La défense cedex, France, 92932
Mainz, Germany, 55127
Budapest, Hungary, 1025
Rome, Italy, 00144
Alphen a/d Rijn, Netherlands
Karachi, Pakistan
Madrid, Spain, 28033
Malmö, Sweden, 202 15
Zurich, Switzerland, CH-8050
United Kingdom
Crawley, United Kingdom, RH11 9RT
Sponsors and Collaborators
Novo Nordisk A/S
Layout table for investigator information
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Novo Nordisk A/S Identifier: NCT01476423    
Other Study ID Numbers: F7HAEM-3521
U1111-1122-5019 ( Other Identifier: WHO )
First Posted: November 22, 2011    Key Record Dates
Last Update Posted: December 23, 2014
Last Verified: December 2014
Keywords provided by Novo Nordisk A/S:
Glanzmann's Thrombasthenia
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemostatic Disorders
Blood Coagulation Disorders
Hematologic Diseases
Vascular Diseases
Cardiovascular Diseases
Hemorrhagic Disorders
Blood Coagulation Disorders, Inherited
Blood Platelet Disorders
Genetic Diseases, Inborn